Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 943

1.

Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis.

Tournier JN, Ulrich RG, Quesnel-Hellmann A, Mohamadzadeh M, Stiles BG.

Expert Rev Anti Infect Ther. 2009 Mar;7(2):219-36. doi: 10.1586/14787210.7.2.219. Review.

PMID:
19254170
2.

Past, imminent and future human medical countermeasures for anthrax.

Baillie LW.

J Appl Microbiol. 2006 Sep;101(3):594-606. Review.

3.

Molecular basis for improved anthrax vaccines.

Brey RN.

Adv Drug Deliv Rev. 2005 Jun 17;57(9):1266-92. Epub 2005 Apr 21. Review.

PMID:
15935874
4.

Anthrax capsule vaccine protects against experimental infection.

Chabot DJ, Scorpio A, Tobery SA, Little SF, Norris SL, Friedlander AM.

Vaccine. 2004 Nov 15;23(1):43-7.

PMID:
15519706
5.

Advances in the development of next-generation anthrax vaccines.

Friedlander AM, Little SF.

Vaccine. 2009 Nov 5;27 Suppl 4:D28-32. doi: 10.1016/j.vaccine.2009.08.102. Review.

PMID:
19837282
6.

Efficacy of recombinant anthrax vaccine against Bacillus anthracis aerosol spore challenge: preclinical evaluation in rabbits and Rhesus monkeys.

Chawla A, Midha S, Bhatnagar R.

Biotechnol J. 2009 Mar;4(3):391-9. doi: 10.1002/biot.200800213. Erratum in: Biotechnol J. 2009 May;4(5):599.

PMID:
19296443
7.

Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components.

Mendelson I, Gat O, Aloni-Grinstein R, Altboum Z, Inbar I, Kronman C, Bar-Haim E, Cohen S, Velan B, Shafferman A.

Vaccine. 2005 Dec 1;23(48-49):5688-97. Epub 2005 Feb 5.

PMID:
16039760
8.

Progress and novel strategies in vaccine development and treatment of anthrax.

Chitlaru T, Altboum Z, Reuveny S, Shafferman A.

Immunol Rev. 2011 Jan;239(1):221-36. doi: 10.1111/j.1600-065X.2010.00969.x. Review.

PMID:
21198675
9.

Induction of protective immunity against lethal anthrax challenge with a patch.

Kenney RT, Yu J, Guebre-Xabier M, Frech SA, Lambert A, Heller BA, Ellingsworth LR, Eyles JE, Williamson ED, Glenn GM.

J Infect Dis. 2004 Aug 15;190(4):774-82. Epub 2004 Jul 13.

PMID:
15272406
10.

[Immunogenicity of the recombinant Bacillus strains with cloned gene of biosynthesis of protective antigen against Bacillus anthracis].

Mikshis NI, Kudriavtseva OM, Bolothikova MF, Shulepov DV, Novikova LV, Popov IuA, Shchukovskaia TN, Drozdov IG, Kutyrev VV.

Mol Gen Mikrobiol Virusol. 2007;(3):15-21. Russian.

PMID:
17886469
11.

Expression of the protective antigen of Bacillus anthracis by Lactobacillus casei: towards the development of an oral vaccine against anthrax.

Zegers ND, Kluter E, van Der Stap H, van Dura E, van Dalen P, Shaw M, Baillie L.

J Appl Microbiol. 1999 Aug;87(2):309-14.

12.

Immunogenicity of a subunit vaccine against Bacillus anthracis.

Chichester JA, Musiychuk K, de la Rosa P, Horsey A, Stevenson N, Ugulava N, Rabindran S, Palmer GA, Mett V, Yusibov V.

Vaccine. 2007 Apr 20;25(16):3111-4. Epub 2007 Jan 22.

PMID:
17280756
13.

Significant passive protective effect against anthrax by antibody to Bacillus anthracis inactivated spores that lack two virulence plasmids.

Enkhtuya J, Kawamoto K, Kobayashi Y, Uchida I, Rana N, Makino S.

Microbiology. 2006 Oct;152(Pt 10):3103-10.

PMID:
17005989
15.

[Progress on the vaccine for anthrax].

Zhan DW, Wang P, Wang LC, Zhang ZS.

Wei Sheng Wu Xue Bao. 2005 Feb;45(1):149-52. Review. Chinese.

PMID:
15847185
16.

Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge.

Huang J, Mikszta JA, Ferriter MS, Jiang G, Harvey NG, Dyas B, Roy CJ, Ulrich RG, Sullivan VJ.

Hum Vaccin. 2007 May-Jun;3(3):90-3. Epub 2007 May 13.

PMID:
17375001
17.

[Role of the components of the S-layer in immunogenicity of Bacillus anthracis].

Mikshis NI, Korsakova AIu, Bolotnikova MF, Novikova LV, Popov IuA.

Zh Mikrobiol Epidemiol Immunobiol. 2006 Jan-Feb;(1):29-32. Russian.

PMID:
16532637
18.

The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.

Doolan DL, Freilich DA, Brice GT, Burgess TH, Berzins MP, Bull RL, Graber NL, Dabbs JL, Shatney LL, Blazes DL, Bebris LM, Malone MF, Eisold JF, Mateczun AJ, Martin GJ.

J Infect Dis. 2007 Jan 15;195(2):174-84. Epub 2006 Dec 6.

PMID:
17191162
19.

An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.

Wimer-Mackin S, Hinchcliffe M, Petrie CR, Warwood SJ, Tino WT, Williams MS, Stenz JP, Cheff A, Richardson C.

Vaccine. 2006 May 1;24(18):3953-63. Epub 2006 Feb 28.

PMID:
16530302
20.

A synthetic peptide vaccine directed against the 2ß2-2ß3 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax.

Oscherwitz J, Yu F, Cease KB.

J Immunol. 2010 Sep 15;185(6):3661-8. doi: 10.4049/jimmunol.1001749. Epub 2010 Aug 9.

Supplemental Content

Support Center